New Clinical Advances in Macular Degeneration
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Ophthalmology".
Deadline for manuscript submissions: 18 November 2024 | Viewed by 77
Special Issue Editors
Interests: macular degeneration
Special Issue Information
Dear Colleagues,
Age-related macular degeneration (AMD) is a progressive macular disease that represents an increasing burden for both patients and healthcare systems worldwide. The clinical manifestations of AMD range from drusen to geographic atrophy and macular neovascularization.
Many attempts have been undertaken to improve disease classification and characterize biomarkers based on spectral-domain optical coherence tomography (SD OCT) and, more recently, OCT angiography. These validated biomarkers can be combined with clinical findings to create promising therapies.
Until a few years ago, there was no proven treatment for dry AMD. However, early and intermediate AMD have recently been recognized as multifactorial entities that respond to various therapies, including complement factors and statins. In addition, several studies have supported the use of anti-complement therapies to reduce the progression of geographic atrophy. On the other hand, many new agents against the vascular endothelial growth factor have recently been approved for the treatment of neovascular AMD. Nevertheless, we still have limited knowledge of the indication criteria and outcomes of these new treatment agents following different treatment protocols.
This Special Issue of the Journal of Clinical Medicine focuses on clinical advances in macular degeneration in terms of diagnostic methods, biomarkers, new therapeutic concepts, agents, and protocols.
Dr. Alaa Din Abdin
Prof. Dr. Berthold Seitz
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- age-related macular degeneration
- anti-vascular endothelial growth factor
- complement factor
- geographic atrophy
- macular neovascularization
- OCT and OCT angiography
- biomarkers
